MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4244/eij-d-22-01022

Медицинская библиотека · EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023

One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloon-expandable valve: the S3U registry.

Cannata Stefano, Gandolfo Caterina, Ribichini Flavio L, van Mieghem Nicolas, Buccheri Sergio, Barbanti Marco, Berti Sergio, Teles Rui Campante, Bartorelli Antonio L, Musumeci Giuseppe, Piva Tommaso, Nombela-Franco Luis, La Spina Ketty, Palmerini Tullio, Adrichem Rik, Esposito Augusto, Lopes Pedro, Olivares Paolo, Annibali Gianmarco, Nicolini Elisa, Marroquin Luis, Tamburino Corrado, Tarantini Giuseppe, Saia Francesco

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Initial data about the performance of the new-generation SAPIEN 3 Ultra (S3U) valve are highly promising. However, evidence about the longer-term performance and safety of the S3U is scarce.

AIMS: We aimed to investigate the 1-year clinical and echocardiographic outcomes of transcatheter aortic valve implantation (TAVI) using the S3U compared with its predecessor, the SAPIEN 3 valve (S3).

METHODS

The SAPIEN 3 Ultra registry included consecutive patients who underwent transfemoral TAVI at 12 European centres with the S3U or S3 between October 2016 and December 2020. One-to-one propensity score (PS) matching was performed to account for differences in baseline characteristics. The primary outcomes of interest were all-cause death and the composite of all-cause death, disabling stroke and hospitalisation for heart failure at 1 year.

RESULTS

The overall study cohort encompassed 1,692 patients treated with either the S3U (n=519) or S3 (n=1,173). The PS-matched population had a total of 992 patients (496 per group). At 1 year, the rate of death from any cause was 4.9% in the S3U group and 6.3% in the S3 group (p=0.743). Similarly, there were no significant differences in the rates of the primary composite outcome (9.5% in the S3 group and 6.6% in the S3U group; p=0.162). The S3U was associated with lower rates of mild paravalvular leak (PVL) compared with the S3 (odds ratio 0.63, 95% confidence interval: 0.44 to 0.88; p<0.01). No significant differences in transprosthetic gradients were observed between the two groups.

CONCLUSIONS

Compared with the S3, the S3U transcatheter heart valve was associated with similar 1-year clinical outcomes but reduced rates of mild PVL.

Для цитирования: Cannata Stefano, Gandolfo Caterina, Ribichini Flavio L, van Mieghem Nicolas, Buccheri Sergio, Barbanti Marco, Berti Sergio, Teles Rui Campante, Bartorelli Antonio L, Musumeci Giuseppe, Piva Tommaso, Nombela-Franco Luis, La Spina Ketty, Palmerini Tullio, Adrichem Rik, Esposito Augusto, Lopes Pedro, Olivares Paolo, Annibali Gianmarco, Nicolini Elisa, Marroquin Luis, Tamburino Corrado, Tarantini Giuseppe, Saia Francesco. One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloon-expandable valve: the S3U registry.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2023. DOI: 10.4244/eij-d-22-01022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.